Τίτλος:
The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases. © 2015 Future Medicine Ltd.
Συγγραφείς:
Simonsen, A.H.
Kuiperij, B.
El-Agnaf, O.M.A.
Engelborghs, S.
Herukka, S.-K.
Parnetti, L.
Rektorova, I.
Vanmechelen, E.
Kapaki, E.
Verbeek, M.
Mollenhauer, B.
Περιοδικό:
Biomarkers in Medicine
Εκδότης:
Future Medicine Ltd
Λέξεις-κλειδιά:
alpha synuclein; amyloid beta protein[1-42]; biological marker; oligomer; tau protein; alpha synuclein; biological marker, Alzheimer disease; Article; body fluid; cerebrospinal fluid; degenerative disease; differential diagnosis; diffuse Lewy body disease; disease severity; early diagnosis; enzyme linked immunosorbent assay; fluorescence resonance energy transfer; gene mutation; human; immunoassay; Parkinson disease; peripheral blood mononuclear cell; protein blood level; protein cerebrospinal fluid level; protein processing; quantitative analysis; saliva level; Shy Drager syndrome; systematic review; animal; clinical chemistry; genetics; Neurodegenerative Diseases, alpha-Synuclein; Animals; Biomarkers; Clinical Chemistry Tests; Humans; Neurodegenerative Diseases
